$HIMS

Hims & Hers reports Q1 earnings May 11 after settling patent dispute with Novo Nordisk, gaining rights to sell Wegovy and Ozempic while discontinuing compounded alternatives.

Enhanced Group debuts on NYSE emphasizing its clinical-backed performance medicine platform over gaming, positioning telehealth and peptide services as core growth driver versus competitors like Hims & Hers.

SpaceX acquires AI coding platform Cursor for $60 billion ($10B upfront), merging space infrastructure with AI capabilities following its xAI investment.

Hims & Hers exploits GLP-1 and estrogen patch shortages, securing steady inventory to position itself as critical pharmaceutical supply anchor amid three-year supply constraints.

Contrarian investors target beaten-down financials, healthcare, and software sectors while cautioning against momentum-driven energy stock rallies despite long-term fundamentals.

Telehealth provider $HIMS faced a data breach affecting customer service records through compromised Zendesk platform in February 2026, triggering class action litigation.

Novo Nordisk launches Wegovy subscription program with monthly pricing from $249-$329, offering up to $1,200 annual savings via telehealth partners.

Over 40 Indian pharma companies launched generic semaglutide after patent expiration, pricing treatments 70% below Novo Nordisk's originals. Market expansion planned globally.

Novo Nordisk wins FDA approval for Wegovy HD, a higher-dose version launching in April across 70,000+ U.S. pharmacies, despite modest stock decline.

Lucid Group tops the most-shorted stocks list as of March 11, 2026, highlighting investor skepticism toward struggling EV manufacturers amid broader market volatility.

BLKBRD Asset Management fully exits $18M Hims & Hers position in Q4 2025, just before company reconciles with Novo Nordisk.

European natural gas surged 68% weekly to 3-year highs amid US-Israeli military actions; weak economic data and political divisions compound energy crisis risks.

Hims & Hers surges 40% after Novo Nordisk partnership resolves litigation, enabling authorized distribution of Wegovy and Ozempic. Stock trades under 20x forward P/E.

Hims & Hers and Novo Nordisk end legal battle, partnering to distribute weight-loss drugs via telehealth. Stock surges 48.67% despite mixed guidance.

U.S. stock futures tumbled as crude oil surged 13-15% amid Iran tensions. Hims & Hers soared 49% on Novo Nordisk settlement; UniQure gained 36% on FDA clarity.

Hims & Hers stock plunged 70% as GLP-1 market competition intensifies and growth slows. Despite challenges, company projects $2.8B 2026 revenue from diversified services.

Hims stock down 75% due to Novo Nordisk lawsuit over semaglutide marketing, but analysts see 150% upside potential and record revenue coming.

Major M&A wave reshapes industries: Danaher acquires Masimo for $9.9B, Devon completes $21.4B energy merger, while Starboard pressures TripAdvisor toward sale.

Hims & Hers to acquire Eucalyptus for $1.15B, expanding into Australia, UK, and Germany. Deal closes mid-2026, marking major international growth push.

Short interest surges in hospitality and EV stocks as investors bet against overvalued companies. Choice Hotels, Lucid, and Avis lead with over 48% short positions.